Bosque Women’s Care Treats First Patient in National Study of New Incision-Free, Transcervical Treatment of Uterine Fibroids

Center is Only Clinical Research Center in New Mexico Chosen to
Participate in Clinical Study; Actively Seeking Additional Patients to
Take Part

ALBUQUERQUE, N.M.–(BUSINESS WIRE)–Bosque Woman’s Care, a medical group that advocates for minimally
invasive treatment solutions for women, announced today that it has
treated its first patient in the SONATA study, an investigational study
of new technology designed to reduce heavy menstrual bleeding caused by
uterine fibroids. Bosque Women’s Care, the only clinical research center
in New Mexico chosen to participate in the study, is actively seeking
other potential patients suffering from uterine fibroids to take part in
the clinical trial. Information on the study can be found at www.sonatatrial.com.

One out of three women will experience uterine fibroids during their
reproductive years. Each year, more than 340,000 women in the U.S.
undergo treatment for uterine fibroids at a cost of more than $6
billion. Symptomatic fibroids can cause painful periods and heavy
menstrual bleeding which impact the quality of life for many women.

Treatment options for uterine fibroids vary from hysterectomy
(surgically removing the uterus) to hormone therapy. “New
uterine-preserving technologies, such as the Sonata System developed by
Gynesonics, are emerging with the intent to treat fibroids in less
invasive, less painful ways,” noted Carrie Swartz, M.D., an OB/GYN and
principal of Bosque Women’s Care.

“The Sonata procedure is an important new, incision-free procedure for
patients with uterine fibroids,” Dr. Swartz said. “It does not require
general anesthesia and is much less invasive than other current options
for women.”

Premenopausal women between 25-50 years of age with fibroids, who suffer
from heavy menstrual bleeding and do not wish to become pregnant, may be
eligible to participate in the study. The study will enroll about 150
patients around the U.S. and the data will be evaluated by the Food and
Drug Administration to determine the availability of the Sonata
procedure in the United States. The Sonata system is CE Marked and
available commercially in Europe.

For more information about this clinical trial, contact the Study
Coordinator, Kasey Alarcon, at 505-399-9724 or kalarcon@lvresearch.com.
Additional information is also available at www.sonatatrial.com.

Contacts

Bosque Woman’s Care
Kasey Alarcon, Study Coordinator
505-399-9724
kalarcon@lvresearch.com